drugset / Trial / NCT02478125
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Phase 1
Terminated
3 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Foundation · collabTaiGen Biotechnology Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Hypothesis: Treatment with Burixafor hydrobromide will effectively mobilize metastatic prostate cancer (PCa) cells (i.e. disseminated tumor cells; DTCs) into the blood from the bone marrow. It has been demonstrated that prostate cancer cells have been mobilized out of the bone marrow of mice utilizing an anti-CXCR4 strategy; making them more susceptible to chemotherapy.
Timeline
- Start
- 2016-07
- Primary completion
- 2017-05
- Completion
- 2017-05
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Burixafor | Unknown | 3.14 mg/kg | Intravenous |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | G-CSF | Unknown | — | Subcutaneous |